Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL2107825

TENOFOVIR ALAFENAMIDE
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1
ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID CHEMBL2107825
Name TENOFOVIR ALAFENAMIDE
Phase Approved
Structure Type MOL
InChI Key LDEKQSIMHVQZJK-CAQYMETFSA-N
Therapeutic ✓ Yes
Active Moiety CHEMBL258501

Known Names

GS-7340 GS-734003 Tenofovir alafenamida Tenofovir alafenamide Vemlidy
3
Targets
7
Activities
2
Assay Types
28
PK Parameters
20
Publications
5
Known Names
12
Indications
1
Mechanisms

Molecular Properties

476.5
MW (Da)
2.97
ALogP
10
HBA
2
HBD
143.5
PSA (Ų)
0.31
QED
0
Ro5 Violations
11
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 2015
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Oral

Flags

Black Box Warning Natural Product Prodrug
USAN Stem -vir
USAN Year 2012

Extended Properties

Molecular Formula C21H29N6O5P
MW 476.47
Aromatic Rings 3
Heavy Atoms 33
NP-Likeness -0.42

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Human immunodeficiency virus type 1 reverse transcriptase inhibitor INHIBITOR Human immunodeficiency virus type 1 reverse transcriptase ✓ ✓

Indications

Virus Diseases Acquired Immunodeficiency Syndrome Hepatitis B, Chronic Hepatitis B, Chronic HIV Infections HIV Infections Severe Acute Respiratory Syndrome Hepatitis D Leukemia, Lymphocytic, Chronic, B-Cell Weight Gain Amyotrophic Lateral Sclerosis Insulin Resistance

ATC Classification

J05AF13
tenofovir alafenamide
Level 1: ANTIINFECTIVES FOR SYSTEMIC USE
Level 2: ANTIVIRALS FOR SYSTEMIC USE

Activity Summary

EC50 4 meas. best 8.3
IC50 3 meas. best 9.0

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
Human immunodeficiency virus 1
CHEMBL378
 IC50 9.0 8.5 1.0 2
Human immunodeficiency virus 1
CHEMBL378
 EC50 8.3 8.3 5.0 2
NON-PROTEIN TARGET
CHEMBL3879801
 EC50 8.3 8.3 5.0 1
Hepatitis B virus
CHEMBL613497
 EC50 7.75 7.75 17.8 1
Hepatitis B virus
CHEMBL613497
 IC50 7.4 7.4 40.0 1

Pharmacokinetic Data

Parameter Value Units Species
CL 37.17 mL.min-1.kg-1 Canis lupus familiaris
CL 42.83 mL.min-1.kg-1 Rattus norvegicus
Cmax - - Canis lupus familiaris
Cmax 2875.31 nM Rattus norvegicus
Cmax 8451.74 nM Rattus norvegicus
Cmax 62585.26 nM Rattus norvegicus
Cmax 34566.71 nM Rattus norvegicus
F 17.0 % Canis lupus familiaris
F 17.0 % Canis lupus familiaris
F 21.0 % Canis lupus familiaris
F 17.0 % Canis lupus familiaris
F 1.7 % Canis lupus familiaris
F 24.7 % Canis lupus familiaris
F 27.7 % Rattus norvegicus
T1/2 1.533 hr Homo sapiens
T1/2 0.4717 hr Homo sapiens
T1/2 0.5167 hr Canis lupus familiaris
T1/2 0.5167 hr Canis lupus familiaris
T1/2 4.59 hr Rattus norvegicus
T1/2 5.46 hr Rattus norvegicus
T1/2 4.44 hr Rattus norvegicus
T1/2 6.2 hr Rattus norvegicus
T1/2 5.2 hr Rattus norvegicus
Tmax 0.375 hr Rattus norvegicus
Tmax 0.25 hr Rattus norvegicus
Tmax 0.25 hr Rattus norvegicus
Tmax 0.25 hr Rattus norvegicus
Vd 16.1 L.kg-1 Rattus norvegicus

Activity Data Samples

Top measurements by pChEMBL value

Target Type Rel. Value Units pChEMBL Assay PubMed
Human immunodeficiency virus 1 IC50 = 1.0 nM 9.0 Antiviral activity against CXCR4-tropic HIV-1 NL4-3 infected in human PHA-stimul... 28682067
Human immunodeficiency virus 1 EC50 = 5.0 nM 8.3 Antiviral activity against Human immunodeficiency virus 1 3B infected in human M... 24686012
NON-PROTEIN TARGET EC50 = 5.0 nM 8.3 Antiviral activity against HIV1 3B infected in human MT2 cells assessed as prote... 27748590
Human immunodeficiency virus 1 EC50 = 5.0 nM 8.3 Antiviral activity against HIV-1 IIIb infected in human MT2 cells assessed as re... 33906050
Human immunodeficiency virus 1 IC50 = 10.0 nM 8.0 Antiviral activity against CCR5 tropic HIV1 BaL infected in human PHA-stimulated... 28682067
Hepatitis B virus EC50 = 17.75 nM 7.75 Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells ... 38246114
Hepatitis B virus IC50 = 40.0 nM 7.4 Antiviral activity against HBV infected in human HepDE19 cells assessed as reduc... 33191744

Literature References

PubMed DOI Target Context # Activities
33191744 10.1021/acs.jmedchem.0c01381 Hepatitis B virus 20
38246114 10.1016/j.bmc.2024.117607 ADMET 18
17145787 10.1128/aac.00968-06 Lysosomal protective protein 4
20409721 10.1016/j.bmc.2010.03.041 ADMET 4
17145787 10.1128/aac.00968-06 Unchecked 3
28792763 10.1021/acs.jmedchem.7b00734 Canis familiaris 3
33191744 10.1021/acs.jmedchem.0c01381 Unchecked 2
- 10.6019/CHEMBL4651402 SARS-CoV-2 2
- 10.6019/CHEMBL4808148 Histone deacetylase 6 2
28682067 10.1021/acs.jmedchem.7b00416 Unchecked 2
33906050 10.1016/j.ejmech.2021.113448 Human immunodeficiency virus 1 2
28682067 10.1021/acs.jmedchem.7b00416 Human immunodeficiency virus 1 2
28792763 10.1021/acs.jmedchem.7b00734 Plasma 2
28792763 10.1021/acs.jmedchem.7b00734 ADMET 2
28792763 10.1021/acs.jmedchem.7b00734 Homo sapiens 1
27748590 10.1021/acs.jmedchem.6b01260 NON-PROTEIN TARGET 1
24686012 10.1016/j.ejmech.2014.03.051 MT2 1
38246114 10.1016/j.bmc.2024.117607 Voltage-gated inwardly rectifying potassium channel KCNH2 1
20409721 10.1016/j.bmc.2010.03.041 PBMC 1
18570362 10.1021/jm8001235 Canis familiaris 1

Data from ChEMBL 36 via Core Engine